Recent advances in plant hepatoprotectives - CIMAP Staff - Central ...

More documents

Recommendations

Info

RECENT ADVANCES IN PLANT HEPATOPROTECTIVES * 765 REFERENCES 1. WHO fact sheet No. 164 and 204, October 2000. 2. NIDDK/NIH. An action plan for liver disease research http://liverplan.niddk.nih.gov. 3. Tome S, Lucey MR. Review article: Current management of alcoholic liver disease. Aliment Pharmacol Ther 2004;19:707–714. 4. Wiart C, Kumar K, Yusof MY, Hamimah H, Fauzi ZM, Sulaiman M. Antiviral properties of Ent-labdene diterpenes of Andrographis paniculata Nees, inhibitors of herpes simplex virus type 1. Phytother Res 2005;19:1069–1070. 5. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G, Aggarwal BB. Role of prooxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 2007;43:568–580. 6. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035– 2063. 7. Flora K, Hahn M, Rosen H, Benner K. Milk Thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139–143. 8. Blumenthal M, Ferrier GKL, Cavaliere C. Total sales of herbal supplements in United States show steady growth. Herbal Gram 2006;71:64–66. 9. Wagner H, Seligmann O. Liver therapeutic drugs from Silybum marianum. In: Chang HM, Yeung HW, Tso WW, Koo A, editors. Advances in Chinese Medicinal Materials Research. Singapore: World Scientific Publ. Co.; 1985. 10. Chavez ML. Treatment of hepatitis C with milk thistle J Herb Pharmacother 2001;1:79–90. 11. Duan L, Carrier DJ, Clausen EC. Silymarin extraction from milk thistle using hot water. Appl Biochem Biotechnol 2004;114:559–568. 12. Leng-Peschlow E. Properties and medical use of flavanolignans (Silymarin) from Silybum marianum. Phytother Res 1996;10 (Suppl 1):S25–S26. 13. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. J Chromatogr A 2003;990:239–245. 14. Lee JI, Hsu BH, Wu D, Barrett JS. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A 2006; 57–68. 15. Blumenthal M Sr, editor. Herbal medicine: Expanded commission E monographs. 1st edition. Newton, MA: Integrative Med Commun; 2000. pp 257-263. 16. Mourelle M, Muriel P, Favari L, Franco T. Prevention of CCl 4 -induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989;3:183–191. 17. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Invest 2002;22(1):51–65. 18. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies in IdB 1016, a silybinphosphatiddylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15: 333–338. 19. Orlando R, Fragasso A, Lampertico M, et al. Silybin kinetics in patients with liver cirrhosis: A comparative study of a silybin-phosphatidylcholine complex and silymarin. Med Sci Res 1990;18:861–863. 20. Flory PJ, Krug G, Lorenz D, Mennicke WH. Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose. Planta Med 1980;38:227–237. 21. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992;42:964–968. 22. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993;31(9):456–460. 23. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin 1978;73(28–29):1060–1065. 24. Kiesewetter E, Leodolter I, Thaler H. Results of two double blind studies on the effect of silymarin in chronic hepatitis. Leber Magen Darm 1977;7(5):318–323. 25. Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protection against hepatic lipid peroxidation by acute ethanol intoxication in the rat. Biochem Phramacol 1985;34:2209–2212. 26. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Invest 2002;22(1):51–65. 27. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silybinin. Hepatol 1996;23:749–754. 28. Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P 450 2 E1. Chem Biol Interact 1994;91:51–63. Medicinal Research Reviews DOI 10.1002/med
766 * NEGI ET AL. 29. Feher J, Lang I, Nekam K, Muzes G, Deak G. Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med Hung 1988;45:265–276. 30. Varga Z, Czompa A, Kakuk G, Antus S. Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavanolignans. Phytother Res 2001;15:608–612. 31. Beckmann-Knopp S, Reitbrock S, Weyhenmeyer R, et al. Inhibitory effects of silybinin on cytochrome P450 enzymes in human liver microsomes. Pharmcol Toxicol 2000;86:250–256. 32. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementarmed 2007;14(2):70–80. 33. Flora K, Hahn M, Rosen H, Benner K. Milk Thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139–143. 34. Kang JS, Jeon YJ, Kim HM, Han SH, Yang KH. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2002;320:138–144. 35. Fraschini F, Demartini G, Esposti D. Pharmacology of Silymarin. Clin Drug Investig 2002;22(1):51–65. 36. Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Aust 1999;170:218–219. 37. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double blind, randomized and multicentre trial. J Hepatol 1998;28:615–621. 38. Puri A, Saxena A, Saxena RP, Saxena KC, Srivastava V, Tandon JS. Immuno-stimulant agents from Andrographis paniculata. J Nat Prod 1993;56:995–999. 39. Visen PKS, Shukla B, Patnaik GK, Dhawan BN. Andrographolide protects rat hepatocytes against paracetamol-induced damage. J Ethnopharmacol 1993;40(2):131–136. 40. Handa SS, Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against carbon tetrachloride. Ind J Med Res 1990;92:276–283. 41. Handa SS, Sharma A. Hepatoprotective activity of andrographolide from Andrographis paniculata against galactosamine and paracetamol intoxication in rats. Ind J Med Res 1990;92:284–292. 42. Choudhury BR, Haque SJ, Poddar MK. Invitro and invivo effects of kalmegh (Andrographis paniculata) extract and andrographolide on hepatic microsomal drug metabolizing enzymes. Planta Med 1987;53:135–140. 43. Medford CJ, Chang RS, Chen GQ, Olmstead MM, Smith KM. A Conformational Study of Diterpenoid Lactones Isolated From the Chinese Medicinal Herb Andrographis paniculata. J Chem Soc Perkin Trans II 1990;2:1011–1016. 44. Chan WR, Willis C, Cava MP, Stein RP. Stereochemistry of andrographolide. Chem Ind 1963;12:495. 45. Rajani M, Shrivastava N, Ravishankara MN. A rapid method for isolation of andrographolide from Andrographis paniculata Nees (Kalmegh). Pharm Biol 2000;38:204–209. 46. Akowuah GA, Zhari A, Norhayati I, Mariam A. HPLC and HPTLC densitometric determination of andrographolides and antioxidant potential of Andrographis paniculata. J Food Composit Anal 2006;19: 118–126. 47. Saxena S, Jain DC, Gupta MM, Bhakuni RS, Mishra HO, Sharma RP. High-performance thin-layer chromatographic analysis of hepatoprotective diterpenoids from Andrographis paniculata. Phytochem Anal 2000;11:34–36. 48. Du Q, Jerz G, Winterhalter PJ. Separation of andrographolide and neoandrographolide from the leaves of Andrographis paniculata using high-speed counter-current chromatography. J Chromatogr A 2003;984:147– 151. 49. Ruengsitagoon W, Anuntakarun K, Aromdee C. Flow injection spectrophotometric determination of andrographolide from Andrographis paniculata. Talanta 2006;69:900–905. 50. Rastogi RP. editor. Compendium of Indian Medicinal Plants. 1998;5:53–54. 51. Choudhury BR, Poddar MK. Andrographolide and kalmegh (A. paniculata) extract: Effect on rat liver and serum transminase. IRCS J Med Sci 1984;12:466–467. 52. Visen PKS, Shukla B, Patnaik GK, Dhawan BN. Andrographolide protects rat hepatocytes against paracetamol induced damage. J Ethnopharmacol 1993;40(2):131–136. 53. Kapoor NK, Chander R, Srivastava V, Tandon JS. Antihepatotoxic activity of diterpenes of Andrographis paniculata (Kal-Megh) against Plasmodium berghei-induced hepatic damage in Mastomys natalensis. Int J Phramacog 1995;33(2):135–138. 54. Shukla B, Visen PK, Patnaik GK, Dhawan BN. Choleretic effect of andrographolide in rats and guinea pigs. Planta Med 1992;58(2):146–149. 55. He X, Li J, Gao H, Qui F, Cui X, Yao X. Four new andrographolide metabolites in rats. Tetrahedron 2003;59:6603–6607. 56. Kapil A, Koul IB, Banerjee SK, Gupta BD. Antihepatotoxic effects of major diterpenoid constituents of Andrographis paniculata. Biochem Pharmacol 1993;46:182–185. 57. Kamdem RE, Sang S, Ho CT. Mechanism of the superoxide scavenging activity of neoandrographolide— A natural product from Andrographolide paniculata Nees. J Agric Food Chem 2002;50:4662–4665. Medicinal Research Reviews DOI 10.1002/med
Page 1 and 2: Recent Advances in Plant Hepatoprot
Page 3 and 4: 748 * NEGI ET AL. The second is the
Page 5 and 6: 750 * NEGI ET AL. hepatoprotective
Page 7 and 8: 752 * NEGI ET AL. been reported to
Page 9 and 10: 754 * NEGI ET AL. O OH O OH HO OH H
Page 11 and 12: 756 * NEGI ET AL. E. Toxicity and S
Page 13 and 14: 758 * NEGI ET AL. done on histopath
Page 15 and 16: 760 * NEGI ET AL. COOH O H COOH O O
Page 17 and 18: 762 * NEGI ET AL. COOH HO 19 CH 3 F
Page 19: 764 * NEGI ET AL. 9. CONCLUSION Her
Page 23 and 24: 768 * NEGI ET AL. 87. Das KC, Das C
Page 25 and 26: 770 * NEGI ET AL. 141. Gowrishanker
Page 27: 772 * NEGI ET AL. His research inte

Recent advances in plant hepatoprotectives - CIMAP Staff - Central ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?